机构：[1]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[3]China National Clinical Research Center for Neurological Diseases, Beijing, China[4]Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Background: Isocitrate dehydrogenase (IDH) mutations are the most common genetic aberrations in gliomagenesis. We aimed to build a high-efficiency prediction gene signature in patients with IDH-mutant glioma. Methods: In total, 167 gliomas from Chinese Glioma Genome Atlas (CGGA) dataset were included for discovery. The Cancer Genome Atlas (TCGA) dataset was used for validation. R language was the main software environment for our statistical operation and graphics. Results: We applied the Time-Dependent ROC Curve (timeROC) method to estimate the gene prediction accuracy of 3 years and 5 years in two datasets. Seven genes were selected for further analysis (AUC >= 0.7 in two datasets). A seven-gene enrichment score was established to predict the overall survival of 3 years and 5 years for IDH- mutant glioma patients. Moreover, the seven-gene signature was an independent prognostic indicator for patients with IDH-mutant glioma. Gene Ontology (GO) Analysis of associated genes revealed signature-related biological process of cell cycle and division. Conclusion: We have identified a seven-gene signature that can provide a more accurate predictor of 3 years and 5 years for patients with IDH-mutant glioma. Moreover, the signature may potentially help neurosurgeons with the clinical personalized management of gliomas.
基金：
National Key Research and Development Plan [2016YFC0902500]; Beijing Science and Technology Plan [Z141100000214009]; Capital Medical Development Research Fund [2016-1-1072]
第一作者机构：[1]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
共同第一作者：
通讯作者：
通讯机构：[1]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[3]China National Clinical Research Center for Neurological Diseases, Beijing, China[4]Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
推荐引用方式(GB/T 7714)：
Wang Qiangwei,Wang Zhiliang,Li Guanzhang,et al.Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling[J].AGING-US.2018,10(8):1977-1988.doi:10.18632/aging.101521.
APA：
Wang, Qiangwei,Wang, Zhiliang,Li, Guanzhang,Zhang, Chuanbao,Bao, Zhaoshi...&Jiang, Tao.(2018).Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling.AGING-US,10,(8)
MLA：
Wang, Qiangwei,et al."Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling".AGING-US 10..8(2018):1977-1988
